Copley Gets a New Life
Executive Summary
After a few volatile years, Copley Pharmaceutical has a new management team, which is gearing up the generics company for growth. Hoechst, which owns 51% of Copley, has said it wants to get out of the generics business and is letting the new management decide on an exit strategy. New CEO Daniel Korpolinski (previously head of CoCensys), believes that Copley's relationships with top national drug store chains remain strong and will help its revival.